Filana Therapeutics Stock
Filana Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Richard Jon Barry
- Employees
- 19
- Market cap
- $34 M
- IPO
- 14/07/2000
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998,…
Filana Therapeutics stock: price history
1D
-7.5%
1W
-13.9%
1M
+2.8%
6M
-59.3%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~6% stronger price swings than usual
Ask the agents about Filana Therapeutics
Filana Therapeutics stock metrics
P/E
-0.81
P/B
0.53
EV/EBITDA
1.16
RETURN ON EQUITY
-13.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.1%
FLOAT SHARES
46,917,599
AVG. DAILY VOLUME (30D)
4,001,781
Insider transactions (SEC)
Barry Richard
Barry Richard
Barry Richard
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Filana Therapeutics stock
What does Filana Therapeutics do?
Filana Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Richard Jon Barry, the company employs around 19 people.
The IPO was on 14/07/2000; the stock trades on NASDAQ under the ticker FLNA.
When does Filana Therapeutics report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 6% stronger than usual.
Does Filana Therapeutics pay a dividend?
No, Filana Therapeutics currently does not pay a dividend.
Which stocks are comparable to Filana Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Filana Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Filana Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.